Victory Capital Management Inc. Has $2.03 Million Position in Repligen Co. (NASDAQ:RGEN)

Victory Capital Management Inc. lessened its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 29.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,624 shares of the biotechnology company's stock after selling 5,564 shares during the period. Victory Capital Management Inc.'s holdings in Repligen were worth $2,028,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Toronto Dominion Bank boosted its stake in shares of Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after buying an additional 75 shares during the period. DekaBank Deutsche Girozentrale grew its position in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock valued at $982,000 after purchasing an additional 89 shares during the last quarter. Ballentine Partners LLC grew its holdings in Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after buying an additional 105 shares during the last quarter. Diversified Trust Co raised its holdings in shares of Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after acquiring an additional 106 shares during the last quarter. Finally, CWM LLC lifted its position in shares of Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 114 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by corporate insiders.

Repligen Price Performance

Shares of RGEN traded up $3.48 during mid-day trading on Monday, reaching $146.06. The company had a trading volume of 578,053 shares, compared to its average volume of 669,038. The company's 50-day moving average is $140.26 and its 200-day moving average is $143.12. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $8.18 billion, a P/E ratio of -394.59, a P/E/G ratio of 4.29 and a beta of 0.96. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. Repligen's quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities analysts anticipate that Repligen Co. will post 1.52 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on RGEN. Benchmark reissued a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Stephens reiterated an "overweight" rating and set a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. UBS Group reduced their price target on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, July 31st. Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target on the stock. Finally, StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.